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There have been significant advances both in humans and
experimental models that relate to the etiopathogenesis of
primary biliary cirrhosis. Many of these advances are
based on the rigorous definition of the antimitochondrial
response, the serologic signature of PBC. First, it is well
established that AMA are directed against members of the
2-oxoacid dehydrogenase complexes (2-OADC), among
which the major epitopes are within the lipoylated
domains of the E2 subunit of the pyruvate dehydrogenase
complex (PDC-E2). Second, autoreactive CD4+ and CD8+
T cells can be detected in PBC peripheral blood, regardless
of the AMA status, and the infiltration of autoreactive
T cells in the liver and periductular spaces is one of the
most prominent immune features. Autoreactive T cells of
both subtypes recognize PDC-E2 sequences overlapping
with the AMA epitopes. An increase in cytotoxic T cell
precursors in the blood in the early stages of the disease
compared to the advanced ones and a 10-fold increase of
specific liver CD8+ T cells compared to peripheral blood
have been demonstrated. Third, additional data on the
immunobiology components of PBC autoimmunity has
been recently obtained in CD4+CD25 high natural regula-
tory T cells which appear to be numerically reduced in
PBC. PBC bile duct cells manifest unique features during
apoptosis while co-culture experiments do not support a
direct role for these cells in determining their immune –
mediated injury. Apoptotic cells are phagocytosed by
BECs and consequently are an exogenous source of auto-
antigens in cholangiocytes, possibly through anti-CD16.
As a result, the impact of putative changes in apoptosis
and autophagy specific to BEC remains to be fully deter-
mined in PBC. Fifth, the innate immune compartment has
been recently investigated in PBC with promising results.
PBC monocytes manifest an increased response to patho-
gen associated stimuli, as indicated by higher levels of pro-
inflammatory cytokines. Further, the hyper-IgM associated
with PBC is secondary to an aberrant innate immune
response, potentially induced by stimulation of toll like
receptor 9 by bacterial CpG-B.
The female preponderance may hold an important key
to PBC etiology. X-linked genes determine gender-related
characteristics at different levels while also regulating the
immune function, particulalry to maintain tolerance.
Major X chromosome defects such as those leading to
Turner’s syndrome or premature ovarian failure are com-
monly characterized by autoimmune comorbidities (parti-
cularly thyroid disease) and, less frequently, cholestasis.
Our group first determined a significantly higher fre-
quency of monosomy of the X chromosome in peripheral
leukocytes (particularly those of the adaptive immune
response, i.e. T and B cells) in women PBC compared to
age-matched control women. Monosomy frequency corre-
lated with age in all three groups, as expected but mono-
somic cells were not microchimeric cells. We further
demonstrated that the X loss in PBC affected was not ran-
dom but affected more frequently one parentally-inherited
chromosome.
Several key animal models of autoimmune cholangitis
have now been described. First, a genomic variant of the
non obese diabetic (NOD) mouse (NOD.c3c4) has been
observed to manifest autoimmune cholestasis with AMA
and ANA positivities in 50%–60% and 80%–90%, respec-
tively. Liver histology demonstrated portal lymphocyte
infiltration with chronic non-suppurative cholangitis and
PBC-like granulomas. Second, a dominant negative form
of trasforming growth factor b (TGFb) receptor II
(dnTGFbRII) mouse develop serum AMA in 100% of
mice. The TGFb receptor II regulates lymphocyte activa-
tion and the appearance of PBC in this model suggests a
specific condition of T cells with impaired TGFb signaling
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in the presence or absence of B cells is involved. Third, the
knockout of interleukin 2 receptor a leads to a murine
phenotype with 100% serum AMA positivity, 80% serum
ANA positivity, and portal lymphocyte infiltration and
vanishing bile ducts. This model is of particular interest
based on the report of autoimmune cholangitis in a pedia-
tric case of IL2Ra deficiency. Fourth, Ae2a,b also develop
autoimmune phenomenon and a PBC-like disease. Finally,
immunization of mice with chemical xenobiotics has also
been shown to lead to a PBC-like disease.
These data and observations will be put in the context of
the key mechanisms, including the role of TLRs in modu-
lating these responses.
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